Literature DB >> 26965912

The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome.

Valentina Guarnotta1, Marco C Amato1, Rosario Pivonello2, Giorgio Arnaldi3, Alessandro Ciresi1, Laura Trementino3, Roberto Citarrella1, Davide Iacuaniello2, Grazia Michetti3, Chiara Simeoli2, Annamaria Colao2, Carla Giordano4.   

Abstract

Cushing syndrome (CS) is characterized by increased morbidity and mortality compared to the general population. However, there are patients who have more clinical aggressive forms than others. Aim of the study is to evaluate whether the degree of hypercortisolism, defined by the number of times urinary free cortisol (UFC) levels exceed the upper limit of the normal range (ULN), is related to the worsening of phenotypic features, as well as metabolic and cardiovascular parameters, in a cohort of CS patients. A cross-sectional study was conducted on 192 patients with active CS, consecutively presenting at the outpatients' clinic of the University Hospitals of Ancona, Naples, and Palermo. Patients were grouped into mild (UFC not exceeding twice the ULN), moderate (2-5 times the ULN), and severe (more than 5 times the ULN) hypercortisolism. Thirty-seven patients (19.3 %) had mild, 115 (59.8 %) moderate, and 40 (20.9 %) severe hypercortisolism. A significant trend of increase among the three groups was demonstrated for 8-, 16-, and 24-h serum cortisol levels (p < 0.001) and serum cortisol after low dose of dexamethasone suppression test (p = 0.001). No significant trend of increase was found regarding phenotype and comorbidities. The degree of hypercortisolism by itself does not appear to be a sufficient parameter to express the severity of CS. Therefore, estimating the severity of CS according to biochemical parameters remains a challenge, while the clinical phenotype and the associated comorbidities might be more useful to assessing the severity of the CS.

Entities:  

Keywords:  Cushing syndrome comorbidities; Cushing syndrome severity; Degree of hypercortisolism; Urinary free cortisol

Mesh:

Substances:

Year:  2016        PMID: 26965912     DOI: 10.1007/s12020-016-0914-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  56 in total

1.  A clinical index for rating severity in Cushing's syndrome.

Authors:  N Sonino; M Boscaro; F Fallo; G A Fava
Journal:  Psychother Psychosom       Date:  2000 Jul-Aug       Impact factor: 17.659

2.  Liquid chromatography-tandem mass spectrometry analysis of urinary free cortisol.

Authors:  Mark M Kushnir; Alan L Rockwood; Gordon J Nelson; Alan H Terry; A Wayne Meikle
Journal:  Clin Chem       Date:  2003-06       Impact factor: 8.327

Review 3.  Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature.

Authors:  R N Clayton; D Raskauskiene; R C Reulen; P W Jones
Journal:  J Clin Endocrinol Metab       Date:  2010-12-30       Impact factor: 5.958

4.  Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up.

Authors:  G Ntali; A Asimakopoulou; T Siamatras; J Komninos; D Vassiliadi; M Tzanela; S Tsagarakis; A B Grossman; J A H Wass; N Karavitaki
Journal:  Eur J Endocrinol       Date:  2013-10-08       Impact factor: 6.664

5.  Clinical correlates of major depression in Cushing's disease.

Authors:  N Sonino; G A Fava; A R Raffi; M Boscaro; F Fallo
Journal:  Psychopathology       Date:  1998 Nov-Dec       Impact factor: 1.944

6.  Elevated cortisol levels in Cushing's disease are associated with cognitive decrements.

Authors:  M N Starkman; B Giordani; S Berent; M A Schork; D E Schteingart
Journal:  Psychosom Med       Date:  2001 Nov-Dec       Impact factor: 4.312

7.  Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing's syndrome.

Authors:  Sachiko Takagi; Akiyo Tanabe; Mika Tsuiki; Mitsuhide Naruse; Kazue Takano
Journal:  Endocr J       Date:  2009-09-29       Impact factor: 2.349

8.  Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol.

Authors:  Luca Manetti; Giuseppe Rossi; Lucia Grasso; Valentina Raffaelli; Ilaria Scattina; Simone Del Sarto; Mirco Cosottini; Aldo Iannelli; Maurizio Gasperi; Fausto Bogazzi; Enio Martino
Journal:  Eur J Endocrinol       Date:  2013-02-15       Impact factor: 6.664

Review 9.  Cushing's Syndrome.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Gaetano Lombardi; Annamaria Colao
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

10.  Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Authors:  Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112

View more
  12 in total

1.  Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease.

Authors:  Valentina Guarnotta; Alessandro Ciresi; Maria Pitrone; Giuseppe Pizzolanti; Carla Giordano
Journal:  Endocrine       Date:  2017-03-17       Impact factor: 3.633

2.  Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.

Authors:  V Guarnotta; G Pizzolanti; A Ciresi; C Giordano
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

3.  The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence".

Authors:  Rosario Pivonello; Giorgio Arnaldi; Carla Scaroni; Carla Giordano; Salvo Cannavò; Davide Iacuaniello; Laura Trementino; Marialuisa Zilio; Valentina Guarnotta; Adriana Albani; Alessia Cozzolino; Grazia Michetti; Marco Boscaro; Annamaria Colao
Journal:  Endocrine       Date:  2019-04-09       Impact factor: 3.633

4.  Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency.

Authors:  V Guarnotta; C Di Stefano; A Santoro; A Ciresi; A Coppola; C Giordano
Journal:  Endocr Connect       Date:  2019-07-01       Impact factor: 3.335

5.  Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study.

Authors:  Valentina Guarnotta; Mariagrazia Irene Mineo; Stefano Radellini; Giuseppe Pizzolanti; Carla Giordano
Journal:  Ther Adv Endocrinol Metab       Date:  2019-08-28       Impact factor: 3.565

6.  Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission.

Authors:  Marie Helene Schernthaner-Reiter; Christina Siess; Alois Gessl; Christian Scheuba; Stefan Wolfsberger; Philipp Riss; Engelbert Knosp; Anton Luger; Greisa Vila
Journal:  Endocrine       Date:  2018-11-22       Impact factor: 3.633

7.  Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing's Disease.

Authors:  Valentina Guarnotta; Antonio Prinzi; Maria Pitrone; Giuseppe Pizzolanti; Carla Giordano
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-11       Impact factor: 3.168

Review 8.  Glucocorticoid excess and COVID-19 disease.

Authors:  Valentina Guarnotta; Rosario Ferrigno; Marianna Martino; Mattia Barbot; Andrea M Isidori; Carla Scaroni; Angelo Ferrante; Giorgio Arnaldi; Rosario Pivonello; Carla Giordano
Journal:  Rev Endocr Metab Disord       Date:  2020-10-06       Impact factor: 6.514

9.  Evaluation of FKBP5 as a cortisol activity biomarker in patients with ACTH-dependent Cushing syndrome.

Authors:  Irina Bancos; Betul Ayse Hatipoglu; Kevin C J Yuen; Lakshmi Chandramohan; Sandeep Chaudhari; Andreas G Moraitis
Journal:  J Clin Transl Endocrinol       Date:  2021-06-06

10.  Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study.

Authors:  Maria Gabriela Suarez; Madeleine Stack; Jose Miguel Hinojosa-Amaya; Michael D Mitchell; Elena V Varlamov; Chris G Yedinak; Justin S Cetas; Brett Sheppard; Maria Fleseriu
Journal:  J Endocr Soc       Date:  2019-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.